A Multicenter Prospective Observational Study on Vertebral Fracture Risk Stratification in Patients With Vertebral Metastases (Valid-METASTRA)
Vertebral fracture is a common clinically significant skeletal related event in cancer patients. Stratification of patients diagnosed with one or more vertebral metastases according to the risk of pathological fracture is an unresolved problem despite the fact that fractures strongly influence the quality of life (QoL) and also the overall survival. The multidimensional nature and the strong patient specificity of the risk for fracture have not been considered in previously published risk estimation models and these methods were developed and validated only on retrospective data focusing on prevalence of life-time fracture which is not really relevant at the time of the diagnosis of a vertebral metastasis. To overcome these shortcomings, the METASTRA models (METASTRA-AI and METASTRA-VPH) and the decision support system (METASTRA-DSS) are developed considering the highest possible level of patient specificity to stratify the individuals according to their risk for fracture in a clinically considerable period (within next 6 months). The prospective data collection and analysis will provide reliability and validity results on the performance of METASTRA tools as well as structured information on user's experience helping the future integration of the developed patient-specific stratification tool into the everyday clinical practice.
The study is a prospective clinical data collection from minimum 200 patients to determine the validity (i.e. Precision) in fracture risk stratification of the METASTRA-AI and METASTRA-VPH computational models and to determine the reliability of METASTRA-AI and METASTRA-VPH as well as human decision making process in patient stratification.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Aron Lazary, MD PhD
- Phone Number: +36304847552
- Email: aron.lazary@bhc.hu
Study Contact Backup
- Name: Julia Szita, PhD
- Phone Number: +36205971605
- Email: julia.szita@bhc.hu
Study Locations
-
-
-
Berlin, Germany
- Department of Neurosurgery Charité Berlin
-
Contact:
- Peter Vajkoczy, Prof. Dr. med
- Email: peter.vajkoczy@charite.de
-
-
-
-
-
Budapest, Hungary, 1126
- Buda Health Center
-
Contact:
- Aron Lazary, MD PhD
- Phone Number: +36304847552
- Email: aron.lazary@bhc.hu
-
-
-
-
-
Bologna, Italy
- IRCCS Istituto ortopedico Rizzoli
-
Contact:
- Giovanni Barbanti Brodano, MD
- Email: giovanni.barbantibrodano@ior.it
-
-
-
-
-
Utrecht, Netherlands
- University Medical Center Utrecht
-
Contact:
- Jorrit-Jan Verlaan, MD PhD
- Email: j.j.verlaan@umcutrecht.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient 18 years or older
- Patient diagnosed with a metastatic tumor in the thoracic and/or lumbar spine (one or more vertebral metastases in the spinal region between T1 and L5 vertebrae)
- Min. 1 vertebra is potentially unstable based on SINS score (SINS is 7-12) and it has not been surgically stabilized previously (level of interest - LOI)
- Adjacent vertebrae are not surgically stabilized at the time of the enrollment
- Patient willing to complete 6-month follow-up
Patient is willing and able to provide written informed consent after the nature of the study has been explained:
- Ability to understand the content of the patient information/ ICF
- Willingness and ability to participate in the study according to the protocol
- Signed and dated EC approved written informed consent
Exclusion Criteria:
- Poor general status at baseline (Karnofsky scale less than 40%)
- Expected life expectancy is less than 3 months at baseline
- Spinal infection
- Ongoing litigation
- Participation in investigational clinical study at the same time or within 3 months
- Vertebral lesion/metastasis from a hematologic condition (e.g. multiple myeloma)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Patients with vertebral metastasis in ThL region
Patient diagnosed with a metastatic tumor in the thoracic and/or lumbar spine (one or more vertebral metastases in the spinal region between T1 and L5 vertebrae)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
new vertebral fracture
Time Frame: in 6 months
|
in 6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EUMET-101080135
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.